Amarin Corp Plc (AMRN)

[lizzy241]

Sleven, more BS.

This firm, along with our co-counsel Wilson Sonsini Goodrich & Rosati, P.C., represents
Plaintiff Dr. Reddy’s Laboratories Inc. (“DRL”) in the above-captioned litigation against Amarin
Pharma, Inc. (“Amarin”). Despite the Court’s directive to temporarily forego litigation in favor
of mediation, the mediation did not progress because Amarin’s representatives did not have
authority to make a meaningful settlement offer. Accordingly, we write to respectfully request:
(1) continuance of discovery, including entry of the enclosed schedule, and (2) reimbursement by
Amarin of DRL’s attorneys’ fees and costs associated with the failed mediation.
At our August 2023 status conferences, Your Honor referred the above-captioned
litigation to mediation with the Honorable Jose L. Linares (and stayed substantial discovery
pending mediation). On October 11, 2023, DRL’s outside counsel and senior in-house counsel
with settlement authority traveled to Newark for the in-person mediation with Judge Linares
(together with counsel for all the parties). Although originally scheduled to last two days, the
mediation ended early afternoon when Judge Linares, who had spent significant time with
Amarin’s counsel (we understand that Amarin’s executives were available by telephone),
advised DRL that Amarin did not have authority to make a meaningful settlement offer. With
settlement progress halted, Judge Linares and DRL agreed to end the mediation early. In
addition to our request for entry of a scheduling order that would speed resolution, DRL requests
the Court to award DRL its fees and costs incurred (and wasted) in connection with the
mediation.